Yahoo
NasdaqCM - Delayed Quote USD

IceCure Medical Ltd (ICCM)

2.2300 +0.0300 (+1.36%)
At close: September 4 at 4:00:01 PM EDT
2.1800 -0.0500 (-2.24%)
After hours: September 4 at 7:17:23 PM EDT
Chart Range Bar
Loading chart for ICCM
  • Previous Close 2.2000
  • Open 2.2000
  • Bid 1.6000 x 200
  • Ask 2.7500 x 200
  • Day's Range 2.1300 - 2.2450
  • 52 Week Range 2.1200 - 42.0000
  • Volume 58,362
  • Avg. Volume 3,307,577
  • Market Cap (intraday) 7.642M
  • Beta (5Y Monthly) 0.44
  • PE Ratio (TTM) --
  • EPS (TTM) -6.9000
  • Earnings Date Nov 18, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 22.67

IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MSense, a multi probe system for the treatment of multiple and larger tumors. The company serves hospitals, interventional radiological centers, ambulatory centers, and private clinics. IceCure Medical Ltd was incorporated in 2006 and is headquartered in Caesarea, Israel.

www.icecure-medical.com

67

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ICCM
87.81%
S&P 500 (^GSPC)
12.75%

1-Year Return

ICCM
92.99%
S&P 500 (^GSPC)
18.71%

3-Year Return

ICCM
93.24%
S&P 500 (^GSPC)
70.93%

5-Year Return

ICCM
99.26%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue 1.28M
Earnings -4.25M
Profit Margin -331.98%

Q2

FY25

Q3

FY25

Q4

FY25

-4M
-3M
-2M
-1M
0
1M
-600.0%
-500.0%
-400.0%

Analyst Insights

View More

Analyst Price Targets

10.00
22.67 Average
2.2300 Current
30.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/14/2026
Analyst Maxim Group
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 3 -> 1

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    7.81M

  • Enterprise Value

    -4.13M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.46

  • Price/Book (mrq)

    0.66

  • Enterprise Value/Revenue

    0.62

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -73.87%

  • Return on Equity (ttm)

    -228.31%

  • Revenue (ttm)

    3.95M

  • Net Income Avi to Common (ttm)

    -16.88M

  • Diluted EPS (ttm)

    -6.9000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    12.03M

  • Total Debt/Equity (mrq)

    0.76%

  • Levered Free Cash Flow (ttm)

    -9.54M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

2.2300 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: